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Mesangial cell expression of proto-oncogene Ets-1 during pro-
gression of mesangioproliferative glomerulonephritis.
Background. Ets-1 is a transactivator of matrix-associated
genes and key factor in neoangiogenesis. The expression of Ets-
1 mRNA and protein was analyzed in healthy rat kidney and in
a model for mesangioproliferative disease without and with in-
hibition of platelet-derived growth factor-B (PDGF-B) activity.
Methods. Immunohistochemistry was performed using a spe-
cific noncrossreacting anti-Ets-1 antibody and included a coun-
terstain with a-smooth muscle actin (a-SMA). Nuclear proteins
from isolated glomeruli were analyzed by Western blotting.
Changes in Ets-1 mRNA levels were detected by in situ hy-
bridization and Northern blotting. PDGF-B antagonism was
performed in nephritic rats by specific aptamers.
Results. The distribution of Ets-1–positive cells in healthy rats
was heterogenous with exclusively nuclear staining of glomeru-
lar, tubular, and vascular cells. Profound changes were detected
in the anti-Thy 1.1 glomerulonephritis. Nuclear Ets-1 staining
was intense in mesangial cells, whereas podocyte and endothe-
lial cell staining was unchanged. The strongest signal was seen
on days 2 to 7. By Western blotting of glomerular proteins a sin-
gle 52 kD band was detected in healthy rats, which was increased
4.5-fold after disease induction. At the same time a 54 kD band
appeared that most likely represents phosphorylated Ets-1. Ets-
1 transcripts were detected in mesangial cells that include exon
IV but lack exon VII. A concordant 6.4-fold up-regulation of
mRNA was detected in glomeruli. Specific PDGF-B antago-
nism by aptamer treatment from days 3 to 7 after disease induc-
tion led to reduced Ets-1 expression on day 7, correlating with
decreased mesangial cell numbers.
Conclusion. A temporal increase of mesangial cell Ets-1 ex-
pression correlates with mesangial cell activation in mesan-
gioproliferative glomerulonephritis. PDGF-B may partially
contribute to the increased expression.
Ets transcription factor family members are at least
transiently expressed by most tissues and are highly reg-
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ulated at different stages during development. The highly
regulated expression in nonhematopoietic tissues has
been demonstrated in human embryos, granulation tis-
sue, and during tumor vascularization in cell types from
different provenience [1]. Elimination of Ets-1 expres-
sion results in inhibition of cell migration and invasion
and angiogenic activity of endothelial cells [2]. In these
processes the c-ets-1 proto-oncogene may transactivate
genes involved in degradation of extracellular matri-
ces and cell migration [3]. Known target genes include,
among others, matrix metalloproteinases (MMP) 1, 3 and
9, as well as integrin-b 3 and urokinase-type plasmino-
gen activator (u-PA) [4–7]. Previous studies have demon-
strated that Ets-1 is expressed by mesangial cells in vitro
and that gelatinase A (MMP-2), the most abundantly
secreted MMP with a direct effect on the prosclerotic
mesangial cells phenotype [8, 9], also constitutes a target
gene [10].
While it is well known that the ets-1 gene is essen-
tial for kidney development (e.g., by activating FREAC,
a winged helix transcriptional factor detected during
nephrogenesis [11]), data on the renal Ets-1 expression
profile in glomerular disease are scarce. Naito et al [12]
reported on the Ets-1 expression pattern during the pro-
gression of rat crescentic glomerulonephritis with a sig-
nificant, 8.8-fold increase of Ets-1–positive glomerular
cells in this model on day 21. In the crescentic glomeru-
lonephritis model glomerular epithelial cells are the main
target and Ets-1 protein was predominantly localized
to glomerular epithelial, endothelial and interstitial cells
with few immunopositive mesangial cells.
The present study was initiated for several reasons: (1)
to assess the Ets-1 expression pattern in healthy kidney
using a specific anti-Ets-1 antibody which does not cross-
react with other members of the large Ets protein family;
(2) to address the question whether activated mesangial
cells express Ets-1 in vivo, given our previous data show-
ing high-level Ets-1 expression by mesangial cells in vitro;
(3) to elucidate the Ets-1 expression pattern in mesangio-
proliferative disease at the protein and transcript level;
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and (4) to identify putative stimuli for increased mesan-
gial cell Ets-1 expression in the rat anti-Thy 1.1 model of
glomerulonephritis.
METHODS
Cells and culture conditions
Rat mesangial cells were established and characterized
as previously described [13] and were grown in RPMI
1640 medium supplemented with 10% fetal calf serum
(FCS), 2 mmol/L L-glutamine, 100 lg/mL of strepto-
mycin, and 100 U/mL penicillin at 37◦C in humidified
5% CO2 in air. An immortalized human mesangial cell
line was kindly provided by B. Banas and cultured as pre-
viously described [14].
Experimental model and experimental design
All animal studies were approved by the Institu-
tional Review Board. Anti-Thy 1.1 mesangial prolifer-
ative glomerulonephritis was induced in male Wistar rats
(Charles River, Sulzfeld, Germany), weighing 140 to 160 g
at the start of the experiment by injection of 1 mg/kg mon-
oclonal anti-Thy 1.1 antibody (clone OX-7) (European
Collection of Animal Cell Cultures, Salisbury, UK).
For the evaluation of the time course of Ets-1 expres-
sion in the anti-Thy 1.1 model, the nephritis was induced
in 12 male Wistar rats. Animals were sacrificed and kid-
ney specimens for immunohistology were obtained prior
to disease induction and on days 2, 7, and 14 after disease
induction (N = 4 for each time point).
Aptamer-based antagonist against platelet-derived
growth factor (PDGF)
The synthesis and characterization of the PDGF-B ap-
tamer (NX1975) have been described in detail [15–17].
For the PDGF-B aptamer study four groups of rats were
studied (N = 4 for each group): (1) rats receiving a total of
4 mg (0.33 mg/injection) of the PDGF-B aptamer [cou-
pled to 15.7 mg 40 kD polyethylene glycol (PEG)]; (2)
rats receiving an equivalent amout of PEG 40-coupled,
scrambled aptamer; (3) rats receiving 400 lL bolus injec-
tions of phosphate-buffered saline (PBS) alone; and (4)
rats receiving PEG 40 alone from days 3 to 7 after disease
induction. Treatment consisted of intravenous bolus in-
jections twice daily of the substances dissolved in 400 lL
PBS (pH 7.4) for a total of eight injections. The treat-
ment duration was chosen to treat rats after the onset of
mesangial cell proliferation which in the OX-7–induced
anti-Thy 1.1 nephritis peaks between days 6 and 9 after
antibody application. Renal biopsies for histologic eval-
uation were obtained on day 7. A renal cortical section
of each rat was obtained for light microscopy and in situ
hybridization.
Immunoperoxidase staining
Four micrometer sections of methyl Carnoy’s fixed
biopsy tissue were processed by an indirect immunoper-
oxidase technique as described previously [18]. Primary
antibodies included a polyclonal rabbit antihuman Ets-
1 antibody (N-276) (Santa Cruz Biotechnology, Heidel-
berg, Germany), a murine monoclonal antibody (clone
1A4) directed against a-smooth muscle actin (a-SMA)
and a murine monoclonal antibody (clone ED-1) to a
cytoplasmic antigen present in monocytes, macrophages,
and dendritic cells. Negative controls consisted of sub-
stitution of the primary antibody with equivalent con-
centrations of normal rabbit or mouse IgG. Additional
negative controls confirming the specificity of the Ets-
1 immunohistology included overnight preincubation of
specific antibody with an excess of the appropriate block-
ing peptide (sc-111P) (Santa Cruz Biotechnology). All
slides were evaluated by two independent observers who
were unaware of the origin of the slides.
Immunohistochemical double-staining
Double immunostaining for the identification of Ets-1
expressing glomerular cells was performed as reported
[19] by first staining the sections for Ets-1 with an anti-
Ets-1 antibody (N-276) (Santa Cruz Biotechnology) us-
ing an indirect immunoperoxidase procedure. To identify
Ets-1 expressing mesangial cells sections were then incu-
bated with the IgG1 monoclonal antibody 1A4 against
a-SMA. Cells were identified as Ets-1 expressing mesan-
gial cells if they showed positive nuclear staining for
Ets-1 and if the nucleus was completely surrounded by
cytoplasm positive for a-SMA. At least 25 glomerular
cross-sections each from four different animals were an-
alyzed. To identify Ets-1 expressing glomerular mono-
cytes/macrophages, sections were incubated with the
monoclonal antibody ED-1 after staining for Ets-1. Neg-
ative controls included omission of either of the primary
antibodies in which case no double-staining was noted
(not shown).
Nuclear cell extracts
Wistar rat kidneys harvested from four animals for
each group (control, 2 hours, 2 and 7 days after dis-
ease induction) were minced by means of a razor blade
and glomeruli were isolated by differential sieving,
washed twice with ice-cold PBS (pH 7.4) without cal-
cium and magnesium and, after resuspension in 3 mL of
ice-cold PBS, were dounce homogenized with a loosely
fitting pestel. Nuclear cell extracts from pooled glomeruli
were prepared as described previously [20] with protein
concentrations determined by the Bio-Rad protein as-
say (Bio-Rad, Hercules, CA, USA) using bovine serum
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albumin (BSA) as standard. Extracts were stored at
−80◦C until performance of Western blot analysis.
Western blot analysis of Ets-1 protein expression
Nuclear extracts (7.5 lg/lane) were electrophoresed on
12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels
and transferred onto nitrocellulose membranes. Mem-
branes were blocked for 2 hours at 22◦C in 10 mmol/L Tris
(pH 8.0), 150 mmol/L NaCl, and 0.05% Tween-20 (TTBS)
containing 2% BSA, followed by three washes with
TTBS and incubation with primary anti-Ets-1 antibody
N-276 (Santa Cruz Biotechnology at 1:2000 dilution),
raised against a peptide mapping with the amino termi-
nal domain (AA 55–70) or anti-Ets antibody C-20 (Santa
Cruz Biotechnology), at 1:2000 dilution. The secondary
antibody consisted of donkey antirabbit horseradish per-
oxidase (HRP)-linked F(ab‘)2 fragment immunglobu-
lin (Amersham/Pharmacia, Freiburg, Germany) (1:5000).
The antibody was visualized by the enhanced chemi-
luminescence (ECL) system (Amersham Pharmacia).
Subsequently, the intensity of the bands was quantified
densitometrically using the Biostep system (Biostep,
Jahnsdorf, Germany). The analysis software was from To-
talLab (Phoretix International, Newcastle, UK).
Electrophoretic mobility shift analysis (EMSA)
Nuclear proteins were included in binding reactions
with radiolabeled RE-2 oligonucleotide probe (TTTAG
CTTTTTCCAGGAACAGCTCAGAAGTCACTTCTT
CCAAGAAGCATT) as previously described [10] and
separated on 4% polyacrylamide, 15% glycerol gels in
a buffer containing 1 × Tris borate/ethylenediamine-
tetraacetic acid (EDTA) followed by autoradiography.
In situ hybridization
In situ hybridization was performed as described [21–
23]. Paraffin sections were cut at 4 lm, mounted on pos-
itively charged slides (SuperfrostTM) and air-dried in an
incubator at 42◦C overnight. Prior to hybridization, sec-
tions were deparaffinized in xylene, rehydrated in graded
alcohols, subjected to gentle proteinase K digestion (for
5 minutes at 37◦C, 1 lg/mL proteinase K in 0.1 mol/L Tris
HCl, pH 8.0, 0.05 mol/L EDTA, and 0.1% SDS), post-
fixed in 4% paraformaldehyde for 15 minutes at room
temperature, acetylated for 10 minutes at room temper-
ature with 0.1 mol/L triethanolamin (pH 8.0) and 25%
acetic acid anhydride, and finally dehydrated in graded
alcohols. 35S-labeled Ets-1 antisense and sense (nega-
tive control) riboprobes were synthesized from the 1.6
kb Sac I/Kpn I fragment of mouse Ets-1 cDNA, cloned
into Bluescript SK plasmid vector. SP6 RNA-polymerase
(Promega, Madison, WI, USA) was used for in vitro tran-
scription (1 hour at 37◦C). Transcription was followed by
thorough DNase I digestion (1 U/lL) (Promega) for 15
minutes at 37◦C of the template, RNA extraction with
TRIzolTM (Gibco BRL, Karlsruhe, Germany) according
to the manufacturer’s protocol, and riboprobe purifica-
tion by phenol/chloroform extraction and SephadexTM
G-50 columns (Boehringer, Mannheim, Germany). Hy-
bridization was carried out for 16 hours at 53◦C [ribo-
probe activity 2 × 104 cpm/lL, hybridization cocktail
(8 mmol/L Tris HCl, pH 8.0, 0.12 mol/L NaCl, 2 mmol/L
EDTA, 0.5 mol/L dithiothreitol, and 50% deionized for-
mamide)]. Slides were stringently washed in 20 mmol/L
Tris HCl, pH 8.0, 0.15 mol/L NaCl, 5 mmol/L EDTA, 0.1
mol/L dithiothreitol, and 50% deionized formamide for
30 minutes at 64◦C. RNase A digestion (0.02 mg/mL) was
then carried out for 45 minutes at 37◦C. After dehydration
in graded alcohols, sections were subjected to autoradio-
graphy for 10 to 14 days (photoemulsion NTB2) (Kodak,
Rochester, NY, USA). Positive signals were visualized
by dark-field illumination of the slides after fluorescent
counterstaining of the nuclei with Hoechst 33258. Nega-
tive control sections were hybridized with the Ets-1 sense
riboprobe.
Reverse transcription-polymerase
chain reaction (RT-PCR)
RT-PCR was performed to detect different splice vari-
ants of the Ets-1 primary transcript with or without
exon IV and/or exon VII. Purified total RNA was re-
verse transcribed into cDNA using SuperScriptTM II
RT kit (Gibco BRL) primed with oligo(dT). RT-PCR
was then performed with two primer pairs flanking
either exon IV (5′-CGATCTCAAGCCGACTCTCA-
3′ and 5′-GTCTTAGGGCGATATGGAGC-3′) or exon
VII (5′-CCCCAGACAACATGTGCATG-3′ and 5′-
TACTCTTTGACTCGGCACCG-3′). The length of the
amplified cDNAs depends upon the presence or the ab-
sence of the exons flanked by the primer pairs (253 or
464 bp in case of exon IV and 211 or 482 bp in case of
exon VII). Products were separated on 2% agarose gels
stained with ethidium bromide.
Northern blotting
Total RNA was extracted from the isolated glomeruli
with the guanidinium isothiocyanate/phenol/chloroform
method using standard procedures [24]. The RNA con-
tent and purity of samples was determined by ultravio-
let spectrophotometry at 260 and 280 nm. For Northern
analysis the RNA was denatured and 10 lg/lane were
electrophoresed through a denaturing 1% agarose/
formaldehyde gel. Integrity of the RNA was assessed by
visualization of ethidium bromide-stained 28S and 18S
rRNA bands. Separated RNA was then transferred onto
a nylon membrane (Hybond NTM; Amersham Pharma-
cia Biotech) by means of capillary blotting and cross-
linked using ultraviolet light at 310 nm. For the detection
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of Ets-1-mRNA the full-length Ets-1 cDNA was ex-
cised from the eukaryotic expression plasmid pEVRF-
ets-1 (kindly provided by Barbara Graves, University of
Utah, Salt Lake City, Utah). Radioactive a-[32P]–labeled
cDNA probes were generated using the Megaprime DNA
labeling system (Amersham Pharmacia Biotech) and hy-
bridization was performed using the QuickHyb hy-
bridization solution (Stratagene, Heidelberg, Germany).
Band intensities were scanned as described for Western
blotting and corrected for the relative intensities of the
28S rRNA signal on the membrane.
Statistical analysis
All values are expressed as mean ± SD. Statistical sig-
nificance (defined as P < 0.05) was evaluated using anal-
ysis of variance (ANOVA) and Bonferroni t tests.
RESULTS
Renal expression of Ets-1 in healthy Wistar rats
A heterogenous distribution of Ets-1–positive cells in
healthy rats (day 0) was found with staining of glomeru-
lar, tubular and vascular cells (Fig. 1A, magnification as
indicated 200- or 600-fold). Exclusively nuclear staining
was detected. Controls included incubation with a non-
specific primary antibody (not shown) and preincuba-
tion of primary antibody with a blocking peptide against
which the N-276 antibody has been raised (Ets-1/peptide)
(Fig. 1A). In both controls no staining was detected indi-
cating the specificity of immunostaining.
With induction of the anti-Thy 1.1 glomerulonephri-
tis an increase of Ets-1–positive glomerular cells was ap-
parent (Fig. 1A) (day 2, day 7, and day 14). In these
experiments a counterimmunostaining for a-SMA was
performed to identify activated mesangial cells. Ets-1
staining was most intense in mesangial cells, whereas
podocyte and endothelial cell staining was rather weak
and unchanged. The strongest signal was seen between
days 2 and 7 with prominent positivity of mesangial cells.
With resolution of mesangial changes on day 14 Ets-1 ex-
pression was still elevated and localized to hypercellular
areas.
In this model infiltrating cells may also contribute to
Ets-1 positivity which was assessed by double-immuno-
staining for Ets-1 (red) and ED-1 (black) as marker for
infiltrating monocytes, macrophages, and dendritic cells.
Ets-1/ED-1–positive glomerular cells were only rarely de-
tected in control animals (Fig. 1B). On day 2 after disease
induction more than 10 Ets-1/ED-1–positive cells were
counted per cross section, the number of which markedly
decreased over time (Fig. 1B). These results indicate that
at the early stages of disease infiltrating cells also con-
tribute to increased Ets-1 expression.
To further determine the specificity of the anti-
Ets-1 antibody N-276 used for immunhistochemistry,
Western blot analysis was performed with nuclear and cy-
tosolic protein extracts obtained from primary rat mesan-
gial cells (Fig. 1C). A single major band with a relative
molecular weight of approximately 52 kD was detected
in nuclear extracts by antibody N-276 (Fig. 1C, lane 4),
whereas only a faint band of similar mobility was detected
with cytosolic proteins (Fig. 1C, lane 5). Conversely, a
multitude of bands were detected with anti-Ets-1 anti-
body C-20, both with nuclear and cytosolic protein prepa-
rations (Fig. 1C, lanes 1 and 2). Control reactions were
performed with omission of primary antibodies (Fig. 1C,
lanes 3 and 6).
Detection of Ets-1 protein in glomeruli from healthy rats
and after induction of anti-Thy 1.1 glomerulonephritis
To quantify glomerular Ets-1 expression in healthy kid-
ney and after induction of anti-Thy 1.1 glomerulonephri-
tis, glomeruli were isolated from four animals for each
time point and analyzed as pooled samples from 2 animals
each. A single major band was detected in control animals
by Western blotting using the specific anti-Ets-1 antibody
N-276 with a molecular size of 52 kD (Fig. 2A). Two hours
after disease induction the average amount of this band
was not significantly changed, yet, a second weak band
of molecular size 54 kD could be detected. After 2 and
7 days, the total amount of Ets-1 protein increased signif-
icantly 2.8- and 4.6-fold, respectively (Fig. 2B), with more
prominent appearance of the 54 kD band. Mesangial cell
Ets-1 expression analyzed in nuclear extracts from a hu-
man mesangial cell line (Fig. 2A, lane 9) and primary rat
mesangial cells (Fig. 2A, lane 10) both exhibited strong
Ets-1 positivity. In these nuclear cell extracts only the
52 kD band could be seen. Furthermore, the previously
identified Ets-1 response element within the gelatinase
A regulatory sequence, denoted response element 2 [10],
was tested for Ets-1 binding in nuclear glomerular ex-
tracts from control animals and 7 days after disease in-
duction. As shown in Figure 2C, Ets-1/response element
2 complex formation was only detected after disease in-
duction, providing indirect evidence for Ets-1–dependent
up-regulation of gelatinase A expression in this nephritis
model.
Detection of Ets-1 mRNA by in situ hybridization
in mesangioproliferative glomerulonephritis
After hybridization of the sections with the Ets-1 anti-
sense probe, only weak Ets-1 expression was demonstra-
ble in the kidney at day 0 (Fig. 3, magnification 300-fold).
In contrast expression increased within glomeruli from
day 2 to day 7 and was still elevated compared to con-
trols on day 14. Hybridization of sections with the Ets-1
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Fig. 6. Glomerular Ets-1 protein and mRNA
expression in diseased rats treated with anti-
platelet-derived growth factor-B (PDGF-B)
aptamers. PDGF-B incubation of human
mesangial cells results in a prolonged, ap-
proximately fourfold up-regulation of Ets-
1 protein expression (A). Representative a-
smooth muscle actin (a-SMA)/Ets-1-double-
immunostaining (B) as well as Ets-1-in situ
hybridization (C) is shown in renal tissue
of PDGF-B aptamer and scrambled control
aptamer-treated animals (B and C, magnifica-
tion 600-fold).
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Fig. 1. Immunostaining of Ets-1 in control Sprague Dawley rats and with mesangioproliferative glomerulonephritis. (A) The distribution of Ets-
1–positive cells in healthy rats [day 0 (d0)] was heterogeneous with exclusively nuclear staining of glomerular, tubular, and vascular cells. Profound
changes of its expression were detected in the anti-Thy 1.1 glomerulonephritis. Ets-1 staining was intense in mesangial cells, whereas podocyte and
endothelial cell staining was rather weak and unchanged. The strongest signal was seen on days 2 to 7 with prominent positivity of mesangial cells.
With resolution of mesangial changes [day 14 (d14)] Ets-1 expression was still elevated and localized to hypercellular areas. Staining specificity of
antibody N-276 was confirmed by preincubation with an Ets-1 peptide (Ets-1/peptide). Magnification as indicated 200- or 600-fold. (B) Double
immunostaining for ED-1 (black) as marker for monocytes, macrophages and dendritic cells and Ets-1 (red) revealed a significant number of ED-1–
positive glomerular cells that were most abundant on day 2 (d2) after disease induction. On day 7 (d7) and day 14 (d14) of the disease ED-1–positive
glomerular cells were rather scarce. (C) Specific immunodetection of Ets-1 in mesangial cells. Western blot analysis of nuclear (NE) and cytosolic
(CE) protein preparations from primary rat mesangial cells was performed with commercial antibodies N-276 (Santa Cruz Biotechnology, lanes 4
and 5) and C-20 (Santa Cruz Biotechnology, lanes 1 and 2). Whereas a single major band of molecular size 52 kD was detected in nuclear extracts
with antibody N-276, a multitude of bands was visible with antibody C-20. Controls were performed with omission of primary antibodies (lanes 3
and 6).
sense probe yielded negative results, as shown for day 7
(Fig. 3, sense probe).
Quantification of Ets-1 mRNA by Northern blot analysis
Total glomerular mRNA from healthy control animals
and animals sacrificed on day 7 after disease induction
was analyzed for Ets-1 expression using a full-length
cDNA probe. As can be seen in Figure 4, a major, 6.4-
fold increase of Ets-1 transcript abundance was apparent
on day 7 after disease induction, supporting the data ob-
tained by in situ hybridization.
Detection of Ets-1 splice variants in mesangial cells
and during the course of mesangioproliferative
glomerulonephritis
Three different splice variants exist of the human Ets 1
primary transcript. They either lack exon IV or exon VII
or both of them. After performing reverse transcription
of mRNA collected from human mesangial cells (Fig. 5,
lane 2), human umbilical vein endothelial cells (Fig. 5,
lane 3), rat mesangial cells (Fig. 5, lane 4) and from rat
mesangial cells expressing full-length Ets-1 expression
plasmid pEVRF (kindly provided from B. Graves, Uni-
versity of Utah, Salt Lake City, Utah) (Fig. 5, lane 5)
the presence of splice variants was analyzed by specific
primer pairs (see Methods section). As can be seen in
Figure 5A, exon IV of Ets-1 was present in all three cell
types whereas exon VII was not detected in any cell type.
Only with introduction of a full-length Ets-1 expression
plasmid exon VII was amplified, which served as posi-
tive control (Fig. 5B, lane 5). To also test for splice vari-
ants during the course of mesangioproliferative glomeru-
lonephritis glomeruli were isolated from healthy rats and
from rats on day 7 after disease induction. In both groups
exons IV and VII of Ets-1 were detected, indicating no
change in splicing during disease (data not shown). How-
ever, one has to keep in mind that a cell-specific splicing
may occur which is not detected by this approach.
1kD
C
220>
97>
66>
45>
30>
21>
14>
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C-20 N-276
CE NE NE CE NE
2 3 4 5 6
Fig. 1. continued.
Ets-1 expression after specific PDGF-B antagonism
in the anti-Thy 1.1 glomerulonephritis
Naito et al [25] previously described stimulation of
Ets-1 expression in vascular smooth muscle cells by
endothelin-1 and PDGF-B. A similar induction of Ets-
1 expression was detected by incubation of human pri-
mary mesangial cells with PDGF-B at a concentration
of 50 ng/mL (Fig. 6A). This stimulatory response was de-
tected within 4 hours and lasted for at least 48 hours. Since
PDGF-B constitutes a major mesangial cell mitogen in
the anti-Thy 1.1 nephritis [17], this raised the question of
PDGF-B–dependent stimulation of Ets-1 expression. To
analyze this interdependence the experimental approach
of PDGF-B inhibition by means of specific anti-PDGF
aptamer infusion was used and compared to scrambled
control aptamer, PEG 40 alone or PBS treatment [15].
Double-immunostained slides (Ets-1 and a-SMA) were
evaluated for whole number of glomerular Ets-1–positive
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Fig. 2. Detection of Ets-1 protein in glomerular nuclear extracts. (A)
Nuclear extracts were pooled from two animals in each group and an-
alyzed by Western blotting using specific anti-Ets-1 antibody directed
against the protein N-terminus (N-276). (B) Bands with a molecular
size of 52 kD could be detected with increased intensities on day 2 (d2)
and day 7 (d7) (2.8- and 4.6-fold, respectively). At the same time a 54
kD band appeared. Control (CON) reactions performed with human
mesangial cells (hMC) and rat mesangial cells (rMC) nuclear extracts
demonstrated the same band size (A, lanes 9 and 10). Furthermore,
Ets-1 binding to the previously characterized gelatinase A response
element-2 (RE-2) was tested with glomerular nuclear proteins from
control animals and on day 7 after disease induction. (C) There was
no complex formation with control nuclear proteins whereas a distinct
RE-2/Ets-1 complex was visualized with extracts after disease induc-
tion.
Probe antisense
d0
d7
d14
Probe sense
d7
Fig. 3. In situ hybridization for Ets-1 in renal tissue of healthy rats and
after induction of mesangioproliferative glomerulonephritis. Only weak
staining for Ets-1 transcripts was seen on day 0 (d0) in the renal cortex.
In contrast expression (light grains) increased within glomeruli from day
2 to day 7 (d7) and again diminishes until day 14 (d14). Hybridization
of a section at day 7 with the Ets-1 sense probe yielded negative results
(sense). Sections after in situ hybridization are shown at 300-fold mag-
nification in dark-field illumination after fluorescent counterstaining of
the nuclei with Hoechst 33258.
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Fig. 4. Northern blot analysis of glomerular Ets-1 expression in mesan-
gioproliferative glomerulonephritis. Healthy control animals (CON)
and animals sacrificed on day 7 (d7) after disease induction were ana-
lyzed for Ets-1 expression using a full-length cDNA probe (A). A major,
6.4-fold increase of Ets-1 transcript abundance was apparent on day 7
after disease induction (B) (mean ± SD).
cells, glomerular Ets-1–positive cells with characteristics
of mesangial cells (a-SMA and Ets-1 double-positive)
and glomerular cells with characteristics of mesangial cell
only (a-SMA–positive and Ets-1–negative). Representa-
tive results of renal Ets-1 immunostaining and in addi-
tion Ets-1 in situ hybridization in PDGF-B aptamer and
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Fig. 5. Expression of Ets-1 splice variants in human and rat mesangial
cells. Three different splice variants exist of the human Ets 1 primary
transcript. They either lack exon IV or exon VII or both of them. In
human mesangial cells (lane 2), human umbilical vein endothelial cells
(lane 3), rat mesangial cells (lane 4), and in rat mesangial cells with
introduced full-length Ets-1 expression plasmid pEVRF (lane 5) the
presence of splice variants was analyzed. Exon IV of Ets-1 was present
in all three cell types (A) whereas exon VII was not detected in rat or
human mesangial cells or endothelial cells. Only with introduction of a
full-length Ets-1 expression plasmid exon VII was amplified, serving as
positive control (B, lane 5).
scrambled control aptamer-treated animals are shown in
Figure 6B and C. Quantification of the immunostain-
ing results obtained with 25 glomerular cross-sections
each from four animals per group demonstrated that
PDGF-B antagonism significantly decreased the number
of whole glomerular Ets-1–positive cells (Fig. 7A) which
obviously resulted from a significantly decreased num-
ber of Ets-1–positive mesangial cells (Fig. 7B). However,
Ets-1–negative mesangial cells were also decreased in the
aptamer-treated group (Fig. 7C).
DISCUSSION
Only few data exist on the expression pattern of the
protooncogene Ets-1 in the healthy kidney and its regu-
lation during development and progression of glomeru-
lar disease. Naito et al [12] recently reported on the
630 Raffetseder et al: Ets-1 expression in mesangioproliferative glomerulonephritis
A
*
Et
s-
1 
(+)
 ce
lls
/gl
om
eru
lum 40
30
20
10
PBS PEG40 Scrambled-
aptamer
PDGF-B
aptamer
B
*
Et
s-
1 
(+)
/α-
sm
o
o
th
 m
us
cl
e 
(+)
 
ce
lls
/g
lo
m
er
ul
um
40
30
20
10
PBS PEG40 Scrambled-
aptamer
PDGF-B
aptamer
C
*
Et
s-
1 
(−)
/α-
sm
o
o
th
 m
us
cl
e 
ac
tin
 (+
) 
ce
lls
/g
lo
m
er
ul
um
10
5
PBS PEG40 Scrambled-
aptamer
PDGF-B
aptamer
Fig. 7. Glomerular Ets-1 protein and mRNA expression in diseased
rats treated with anti-platelet-derived growth factor-B (PDGF-B) ap-
tamers. Quantification of whole glomerular Ets-1–positive cells (A),
a-smooth muscle actin (a-SMA)/Ets-1-double-positive cells (B), and
a-SMA single-positive cells (C). ∗Indicates significant (P < 0.05) less
positive cells in aptamer group compared to control groups. Abbrevia-
tions are PBS, phosphate-buffered saline; PEG 40, polyethylene glycol.
expression of Ets-1 mRNA and protein in a rat model
of accelerated nephrotoxic serum-induced antiglomeru-
lar basement membrane nephritis. They found significant
up-regulation of Ets-1, both at the transcript and protein
level during the course of nephrotoxic disease. In con-
trol rat kidneys, Ets-1 positivity was only occasionally
detected in the glomeruli and tubulointerstitium. Dur-
ing antiglomrular basement membrane nephritis Ets-1
was mainly noted in glomerular epithelial cells; however,
mesangial cells were not found to be Ets-1–positive.
Our results with a monospecific anti-Ets-1 antibody
yielded Ets-1–positive cells in glomerular and intersti-
tial cells of the healthy kidney, which was significantly
more widespread than that observed by Naito et al [12].
Specificity of our staining was confirmed by appropri-
ate negative controls, including substitution of the pri-
mary antibody by an unrelated IgG and prior incubation
of the primary antibody with the immunizing peptide.
Furthermore, a single major band with a relative molec-
ular weight of 52 kD could be detected in nuclear protein
preparations by Western blotting, which corresponds to
the known molecular weight of Ets-1. In our hands, the
antibody used by Naito et al, which is directed against
the carboxy-terminus of Ets-1 (C-20 Santa Cruz Biotech-
nolgy, Santa Cruz, CA, USA), recognized a broad range
of Ets-related proteins but displayed only very weak
staining of Ets-1 protein (Fig. 1C). However, a direct com-
parison of our findings with the C-20 antibody and that
used by Naito et al has to be made with great caution,
given potential differences in antibody preparation and
nonidentical lots.
In kidney tissue of animals with mesangioprolifera-
tive glomerulonephritis counterstaining against a-SMA
allowed for the specific visualization of activated mesan-
gial cells and immunolocalization of mesangial cells as
being strongly Ets-1–positive. Accordingly, we identified
mesangial cells as the main source of glomerular Ets-1
expression during anti-Thy 1.1 nephritis. The increased
glomerular expression of Ets-1 in this model was found
both at the transcript as well as at the protein level, with
an increase of 4.5-fold and 6.4-fold compared to controls,
respectively. Furthermore, a distinct 54 kD band was de-
tected by Western blotting after disease induction that
most likely represents phosphorylated protein. Mesan-
gial cells as the main source of glomerular Ets-1 in the
anti-Thy 1.1 nephritis were also suggested by the results
of in situ hybridization. The increase of Ets-1 expres-
sion coincided with the time-course of the mesangiopro-
liferative phase of the spontaneously reversible model
of anti-Thy 1.1 nephritis [26]. Given our in vitro find-
ing of a mesangial cell specific up-regulation of gelati-
nase A expression by Ets-1 [10], this transcription factor
may also orchestrate gelatinase A gene expression which
is reported to be increased during the course of mesan-
gioproliferative glomerulonephritis [27]. The previously
identified Ets-1 responsive element within the gelatinase
A regulatory sequence was tested for Ets-1 binding by
EMSA. Significant nuclear Ets-1 protein binding to this
element was detected 7 days after disease induction com-
pared to absent binding in control animals. This suggests a
Raffetseder et al: Ets-1 expression in mesangioproliferative glomerulonephritis 631
transcriptional up-regulation of the gelatinase A gene
with disease induction; however, a direct visualization of
MMP-2 enzyme and colocalization with Ets-1 expression
by immunohistochemistry was not possible as numerous
antibodies tested did not reveal a specific staining pattern.
Naito et al [12] reported on a temporal correlation
of MMP-3 and Ets-1 expression; however, few cells
exhibited coexpression of MMP-3 and Ets-1 by dou-
ble immunostaining. Ets-1 is known to orchestrate the
expression of several enzymes involved in extracellu-
lar matrix degradation and remodeling that include
collagenase-1 (MMP-1) [28], stromelysin (MMP-3, [29])
and 92 kD type IV collagenase (MMP-9 [30]). Further-
more, several genes encoding extracellular matrix pro-
teins like osteopontin and tenascin are also Ets-1 tar-
get genes [31], indicating that Ets-1 may play a key
role for coordinated matrix synthesis and degradation in
nephritis.
Three different splice variants exist of the human Ets 1
primary transcript. They either lack exon IV or exon VII
or both of them and are translated into proteins which
probably differ by their functional properties [32–36]. Ex-
pression of these splice variants were analyzed in human
and rat mesangial and human endothelial cells. Exon VII
encodes parts of the DNA-binding domain of Ets-1, other
parts being encoded by exons VIII and IX [33, 37]. The
translation product of this splice variant (p42 Ets-1) might
thus display other DNA binding properties than the full-
length Ets 1 protein. In colon carcinoma cells p42 Ets-1
has been found to rescue Fas-induced apoptosis [38, 39].
The fact that human astrocytomas express, in contrast
to breast cancers, exclusively the full-length c-Ets 1 tran-
script [23] suggests the existence of tissue-specific splicing
mechanisms of the c-Ets 1 primary transcript [40]. For hu-
man as well as rat mesangial cells the absence of exon VII
was detected, which may affect transcriptional activity of
this transcription factor.
Finally, we assessed whether glomerular Ets-1 expres-
sion is regulated by PDGF-B in vivo. PDGF-B is a known
stimulator of Ets-1 expression in rat vascular smooth
muscle cells [25] and our results with primary human
mesangial cells demonstrate an approximately fourfold
up-regulation after PDGF-B stimulation. Our approach
with application of specific anti-PDGF-B aptamers from
days 3 to 7 after disease induction results in a major de-
crease of mesangial cell proliferation [15, 17]. We here
demonstrated that PDGF-B antagonism results in a sig-
nificantly lower number of Ets-1–positive mesangial cells
on day 7 of the disease with overall Ets-1–positive cells
being also significantly decreased. It is concluded that the
significantly decreased number of Ets-1–positive cells in
the intervention group is found because of the overall re-
duced mesangial cell number [15]. PDGF-B may thus act
as an inductor of Ets-1 expression in mesangioprolifera-
tive disease.
From the results obtained it remains unclear whether
reduced Ets-1 expression is just a consequence of re-
duced mesangial cell number or if indeed reduced PDGF-
driven Ets-1 expression is responsible. And it remains
enigmatic whether Ets-1 is as a protective regulator
which helps in restoring glomerular changes ad inte-
grum or acts as a progression factor. In this respect it
is noteworthy that Ets-1 knockout mice exhibit various
glomerular abnormalities, including sclerosis, atrophy,
and markedly fewer and immature glomeruli arguing
in favor of Ets-1 as a protective factor. The answer
will be obtained after specific inhibition of Ets-1 in dif-
ferent forms of glomerulonephritis (e.g., by introduc-
ing antisense-oligonucleotides, dominant-negative acting
mutants or synthetic DNA-binding ligands [1, 41–43].
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